IN2014MN02522A - - Google Patents

Download PDF

Info

Publication number
IN2014MN02522A
IN2014MN02522A IN2522MUN2014A IN2014MN02522A IN 2014MN02522 A IN2014MN02522 A IN 2014MN02522A IN 2522MUN2014 A IN2522MUN2014 A IN 2522MUN2014A IN 2014MN02522 A IN2014MN02522 A IN 2014MN02522A
Authority
IN
India
Application number
Other languages
English (en)
Inventor
Michael Baumann
Original Assignee
Molecular Partners Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Partners Ag filed Critical Molecular Partners Ag
Publication of IN2014MN02522A publication Critical patent/IN2014MN02522A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/49Platelet-derived growth factor [PDGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/10Ophthalmic agents for accommodation disorders, e.g. myopia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2318/00Antibody mimetics or scaffolds
    • C07K2318/20Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
IN2522MUN2014 2012-06-28 2014-12-11 IN2014MN02522A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12174020 2012-06-28
PCT/EP2013/063488 WO2014001442A1 (en) 2012-06-28 2013-06-27 Designed ankyrin repeat proteins binding to platelet-derived growth factor

Publications (1)

Publication Number Publication Date
IN2014MN02522A true IN2014MN02522A (es) 2015-07-17

Family

ID=48699826

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2522MUN2014 IN2014MN02522A (es) 2012-06-28 2014-12-11

Country Status (16)

Country Link
US (2) US9163070B2 (es)
EP (1) EP2867360B1 (es)
JP (1) JP2015522576A (es)
KR (1) KR20150023957A (es)
CN (1) CN104508129A (es)
AU (1) AU2013283296A1 (es)
BR (1) BR112014032316A2 (es)
CA (1) CA2877584A1 (es)
HK (1) HK1209156A1 (es)
IL (1) IL236428A0 (es)
IN (1) IN2014MN02522A (es)
MX (1) MX2014015825A (es)
RU (1) RU2014150224A (es)
SG (1) SG11201408196RA (es)
WO (1) WO2014001442A1 (es)
ZA (1) ZA201408872B (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR081361A1 (es) 2010-04-30 2012-08-29 Molecular Partners Ag Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
JP6173216B2 (ja) 2010-11-26 2017-08-02 モレキュラー・パートナーズ・アーゲーMolecular Partners Ag 設計アンキリンリピートタンパク質のための改善されたキャッピングモジュール
DK2846836T3 (da) 2012-05-07 2019-11-11 Allergan Inc Fremgangsmåde til behandling af amd hos patienter, der er refraktære overfor anti-vegf-terapi
EP2738180A1 (en) 2012-11-30 2014-06-04 Molecular Partners AG Binding proteins comprising at least two binding domains against HER2.
JP6486908B2 (ja) 2013-05-31 2019-03-20 モレキュラー パートナーズ アクチェンゲゼルシャフト 肝細胞増殖因子に結合する設計アンキリン反復タンパク質
ES2834849T3 (es) 2014-07-07 2021-06-18 Yeda Res & Dev Método de diseño computacional de proteínas
WO2016023898A2 (en) * 2014-08-11 2016-02-18 Medimmune Limited Intracellular antigen binding
SG11201703428SA (en) 2014-11-10 2017-05-30 Hoffmann La Roche Bispecific antibodies and methods of use in ophthalmology
CN107074942A (zh) 2014-11-10 2017-08-18 豪夫迈·罗氏有限公司 抗‑IL‑1β抗体和使用方法
WO2016075036A1 (en) 2014-11-10 2016-05-19 F. Hoffmann-La Roche Ag Anti-pdgf-b antibodies and methods of use
KR20170082594A (ko) 2014-11-10 2017-07-14 에프. 호프만-라 로슈 아게 항-ang2 항체 및 사용 방법
ES2953482T3 (es) 2015-04-02 2023-11-13 Molecular Partners Ag Dominios de repetición de anquirina diseñados con especificidad de unión para la albúmina sérica
US10283384B2 (en) * 2015-04-27 2019-05-07 Taiwan Semiconductor Manufacturing Co., Ltd. Method for etching etch layer and wafer etching apparatus
ES2953516T3 (es) 2016-09-22 2023-11-14 Molecular Partners Ag Proteínas de unión recombinantes y su uso
US10037890B2 (en) * 2016-10-11 2018-07-31 Lam Research Corporation Method for selectively etching with reduced aspect ratio dependence
WO2018165046A1 (en) 2017-03-07 2018-09-13 Igc Bio, Inc. A computational pipeline for antibody modeling and design
EP3623382A1 (en) 2018-09-14 2020-03-18 Universität Zürich Ligands to gm-csf or gm-csf-receptor for use in leukemia in a patient having undergone allo-hct
US11655293B2 (en) 2018-02-22 2023-05-23 Universitat Zurich Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT
WO2019180243A1 (en) 2018-03-22 2019-09-26 Charité-Universitätsmedizin Berlin Crispr associated protein reactive t cell immunity
EP3807401A1 (en) 2018-06-15 2021-04-21 Universität Bern LIGANDS TO LIGHT OR ITS RECEPTOR LTßR FOR USE IN HAEMATOLOGIC MALIGNANCIES
JP2022504472A (ja) 2018-10-08 2022-01-13 ウニベルシテート チューリッヒ Her2結合四量体ポリペプチド
WO2020104627A1 (en) 2018-11-21 2020-05-28 Universität Zürich Photochemically induced conjugation of radiometals to small molecules, peptides and nanoparticles in a simultaneous one-pot reaction
EP3677911A3 (en) 2019-01-03 2020-07-29 Universität Basel Use of non-agonist ligands for suppression of metastasis
WO2020144378A1 (en) 2019-01-11 2020-07-16 Universitätsspital Basel Sglt-2 inhibitors or il-1r antagonists for reduction of hypoglycaemia after bariatric surgery
EP3953712A1 (en) 2019-04-10 2022-02-16 Universität Zürich A method for determining the likelihood of a patient being responsive to cancer immunotherapy
UY38739A (es) 2019-06-04 2020-12-31 Molecular Partners Ag Proteínas multiespecíficas
EP3980045A1 (en) * 2019-06-04 2022-04-13 Molecular Partners AG Recombinant fap binding proteins and their use
WO2021044050A1 (en) 2019-09-05 2021-03-11 Genome Biologics Ug Inhibition of mthfd1l for use in hypertrophic heart disease and heart failure
CN115003689A (zh) 2019-12-11 2022-09-02 分子合作伙伴股份公司 具有改变的表面残基的经设计的锚蛋白重复结构域
WO2021122813A1 (en) 2019-12-16 2021-06-24 Universität Basel Angiogenesis promoting agents for prevention of metastatic cancer
WO2021176008A1 (en) 2020-03-04 2021-09-10 Cornell University Agents targeting baf155 or brg1 for use in treatment of advanced prostate cancer
WO2021204781A1 (en) 2020-04-06 2021-10-14 Universität Zürich Artc1 ligands for cancer treatment
JP2023525518A (ja) 2020-05-06 2023-06-16 モレキュラー パートナーズ アクチェンゲゼルシャフト 新規アンキリンリピート結合タンパク質とその用途
AU2021271129A1 (en) 2020-05-14 2022-12-15 Molecular Partners Ag Multispecific proteins
WO2021239844A1 (en) 2020-05-27 2021-12-02 Universitätsspital Basel Sglt-2 inhibitors or il-1r antagonists for reduction of hypoglycaemia in prediabetes
WO2021239999A1 (en) 2020-05-28 2021-12-02 Universität Zürich Il-12 pd-l1 ligand fusion protein
WO2022038193A1 (en) 2020-08-18 2022-02-24 Universität Zürich A cd25-biased anti-il-2 antibody
US20240108746A1 (en) 2020-12-16 2024-04-04 Molecular Partners Ag Novel slow-release prodrugs
WO2022171831A1 (en) 2021-02-11 2022-08-18 Universität Zürich Use of markers found on lymph node metastatic samples for the prognosis of breast cancer
EP4304729A1 (en) 2021-03-09 2024-01-17 Molecular Partners AG Novel darpin based cd123 engagers
EP4305063A1 (en) 2021-03-09 2024-01-17 Molecular Partners AG Protease cleavable prodrugs
BR112023018293A2 (pt) 2021-03-09 2023-10-31 Molecular Partners Ag Acopladores de célula t multiespecíficos à base de darpin
WO2022190010A1 (en) 2021-03-09 2022-09-15 Molecular Partners Ag Novel darpin based cd33 engagers
CA3227299A1 (en) 2021-08-05 2023-02-09 Immunos Therapeutics Ag Pharmaceutical compositions comprising hla fusion proteins
IL310617A (en) 2021-08-05 2024-04-01 Immunos Therapeutics Ag Combination drugs that include HLA FUSION proteins
WO2023021006A1 (en) 2021-08-16 2023-02-23 Universität Zürich Il-1 targeting agents for treatment of pitiyriasis rubra pilaris
WO2023036849A1 (en) 2021-09-07 2023-03-16 ETH Zürich Identifying and predicting future coronavirus variants
EP4163380A1 (en) 2021-10-08 2023-04-12 ETH Zurich Device and method for manipulation of extracellular vesicles
WO2023110983A1 (en) 2021-12-14 2023-06-22 Molecular Partners Ag Designed repeat domains with dual binding specificity and their use
WO2023110942A1 (en) 2021-12-14 2023-06-22 Charité-Universitätsmedizin Berlin Prevention of impaired fracture healing
EP4260907A1 (en) 2022-04-11 2023-10-18 Universität Zürich Agents for treatment of endometriosis and other benign gynecological neoplasms
WO2024002914A1 (en) 2022-06-27 2024-01-04 Charité-Universitätsmedizin Berlin Prediction of, and composition to improve, tendon healing
WO2024028278A1 (en) 2022-08-01 2024-02-08 Molecular Partners Ag Charge modified designed repeat domains and their use
WO2024038307A1 (en) 2022-08-19 2024-02-22 Novartis Ag Dosing regimens for sars-cov-2 binding molecules

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5094941A (en) * 1987-12-31 1992-03-10 Zymogenetics, Inc. Monoclonal antibodies to PDGF
ATE151110T1 (de) 1988-09-02 1997-04-15 Protein Eng Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5348867A (en) 1991-11-15 1994-09-20 George Georgiou Expression of proteins on bacterial surface
CA2196496A1 (en) 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
WO1998048008A1 (en) 1997-04-23 1998-10-29 Plueckthun Andreas Methods for identifying nucleic acid molecules encoding (poly)peptides that interact with target molecules
WO2000032823A1 (en) 1998-12-02 2000-06-08 Phylos, Inc. Dna-protein fusions and uses thereof
CA2421447C (en) * 2000-09-08 2012-05-08 Universitat Zurich Collections of repeat proteins comprising repeat modules
JP2005512962A (ja) * 2001-09-20 2005-05-12 アレクシオン ファーマシューティカルズ, インコーポレイテッド 抗pdgf抗体および設計抗体の産生方法
CN102813923B (zh) * 2003-08-27 2015-04-01 奥普索特克公司 用于治疗眼新血管疾病的组合治疗
US20080206201A1 (en) * 2004-11-12 2008-08-28 Rudolf Beier Recombinant Newcastle Disease Virus
WO2006129828A2 (en) * 2005-05-31 2006-12-07 Canon Kabushiki Kaisha Target substance capturing molecule
AU2006268780B2 (en) 2005-07-08 2011-03-24 University Of Zurich Phage display using cotranslational translocation of fusion polypeptides
EP1996220B2 (en) 2006-03-06 2023-08-16 Amunix Operating Inc. Unstructured recombinant polymers and uses thereof
SI2173890T1 (sl) 2007-06-21 2011-06-30 Univ Muenchen Tech Biološko aktivni proteini, ki imajo povečano in vivo in/ali in vitro stabilnost
AU2008328726B2 (en) * 2007-11-30 2014-06-12 Glaxo Group Limited Antigen-binding constructs
WO2009100990A1 (en) * 2008-02-13 2009-08-20 Dsm Ip Assets B.V. Process for the production of a peptide
WO2009115919A2 (en) * 2008-03-19 2009-09-24 Institut Pasteur Reagentless fluorescent biosensors comprising a designed ankyrin repeat protein module, rational design methods to create reagentless fluorescent biosensors and methods of their use
US8901076B2 (en) 2008-11-03 2014-12-02 Molecular Partner AG Binding proteins inhibiting the VEGF-A receptor interaction
TW201120210A (en) * 2009-11-05 2011-06-16 Hoffmann La Roche Glycosylated repeat-motif-molecule conjugates
AR081361A1 (es) 2010-04-30 2012-08-29 Molecular Partners Ag Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
JP6173216B2 (ja) * 2010-11-26 2017-08-02 モレキュラー・パートナーズ・アーゲーMolecular Partners Ag 設計アンキリンリピートタンパク質のための改善されたキャッピングモジュール
EP2702069A4 (en) * 2011-04-29 2015-04-29 Janssen Biotech Inc IL4 / IL13 BINDING REPEAT PROTEINS AND USES THEREOF

Also Published As

Publication number Publication date
HK1209156A1 (en) 2016-03-24
US20150368302A1 (en) 2015-12-24
JP2015522576A (ja) 2015-08-06
CN104508129A (zh) 2015-04-08
AU2013283296A1 (en) 2015-02-05
EP2867360A1 (en) 2015-05-06
MX2014015825A (es) 2015-08-10
CA2877584A1 (en) 2014-01-03
IL236428A0 (en) 2015-02-26
US20140005125A1 (en) 2014-01-02
KR20150023957A (ko) 2015-03-05
EP2867360B1 (en) 2019-05-08
SG11201408196RA (en) 2015-03-30
WO2014001442A1 (en) 2014-01-03
BR112014032316A2 (pt) 2017-06-27
ZA201408872B (en) 2016-05-25
US9163070B2 (en) 2015-10-20
RU2014150224A (ru) 2016-08-20

Similar Documents

Publication Publication Date Title
IN2014MN02522A (es)
BR112014029417A2 (es)
BR112014017635A2 (es)
BR112014023806A2 (es)
BR112014017614A2 (es)
BR112014017625A2 (es)
BR112014017659A2 (es)
BR112014017646A2 (es)
BR112014017638A2 (es)
BR112014023567A2 (es)
BR112014017607A2 (es)
BR112014017974A2 (es)
BR112014019700A2 (es)
BR112014017634A2 (es)
BR112014017609A2 (es)
BR112014017673A2 (es)
BR112014017644A2 (es)
BR112014018153A2 (es)
BR112014017647A2 (es)
BR112014017618A2 (es)
BR112014017630A2 (es)
BR112014017652A2 (es)
BR112014017621A2 (es)
BR112014017627A2 (es)
BR112014017623A2 (es)